The battle on the field continues. Monsanto (MON) and Syngenta (SYT) are expected to enter the seed business with a strong bid. Both companies stand at the top of the agricultural inputs industry, and continue to look for ways to improve performance. Let us see what some gurus think about their future prospects, and if they see them fit for a long term investment.
Research over Legal Battles
Monsanto is the largest crop protection and seed producer in the industry with a market cap of more than $54 million. The company has recently made the news in association to a hay producer who was denied the right of export due to genetic contamination. Stock price, however, remains on a steep climb and operations continue as normal.
Results for the last quarter were strong thanks to a higher demand for corn in Latin America and Eastern Europe. In line, earnings and revenues displayed noticeable improvements year-over-year that helped increase cash volumes. The success on performance allows the company to continue feeding its research and development pipeline in the short term. Also, the firm is well known for introducing products to help farmers improve yields and reduce production costs. Hence, the business created an important economic moat for itself.
Top 5 Managed Healthcare Companies To Buy Right Now: Bk Of Nova Scotia Com Npv (BNS.TO)
The Bank of Nova Scotia provides various personal, commercial, corporate, and investment banking services in Canada and internationally. It operates in four segments: Canadian Banking, International Banking, Global Wealth & Insurance, and Global Banking & Markets. The Canadian Banking segment provides retail and small business banking products and services, including deposit accounts, investments, mortgages, loans, debit cards, credit cards, and related creditor insurance products to individuals and small businesses; and commercial banking solutions comprising deposit, lending, and cash management solutions to medium and large businesses. This segment offers its products through a network of 1,038 branches and 3,800 automated banking machines, and specialized sales teams, as well as through Internet, mobile, and telephone banking in Canada. The International Banking segment provides retail and commercial banking services to customers located in the Caribbean, Latin America , Central America, and Asia through a network of approximately 3,000 branches and offices, 7,500 automated banking machines, in-store banking kiosks, and specialized sales forces, as well as through mobile, Internet, and telephone banking. The Global Wealth & Insurance segment provides wealth management services, comprising asset management and client-facing services; and insurance products and services, such as creditor, life and health, home, and auto and travel insurance products. The Global Banking & Markets segment offers corporate lending, equity and debt underwriting, and mergers and acquisitions advisory services, as well as fixed income, derivatives, prime brokerage, securitization, foreign exchange, equity sales, trading and research, energy and agricultural commodities, and precious and base metals to corporate, government, and institutional investor clients. The Bank of Nova Scotia was founded in 1832 and is based in Toronto, Canada.
Advisors' Opinion:- [By Roadmap2Retire]
Monthly Contributions: I add to my positions in the following stock and funds on a monthly basis:
Claymore S&P US Dividend Growers ETF (CUD.TO) is an ETF of 83 dividend growers and provides me with exposure to excellent corporations across all sectors. The ETF has a 1.8% yield and pays distributions monthly. iShares Canadian Financial Monthly Income Fund (FIE.A.TO) is an ETF of 24 Canadian financial equities (70%) and bonds (30%). The fund yields 6.5% and pays distributions monthly. Scotia Canadian Balanced Fund (mutual fund) is an index fund tracking the Canadian S&P/TSX Composite Index and the DEX Universe Bond Index. The fund yields 0.52% and pays distributions quarterly. The Bank of Nova Scotia (BNS.TO) is the third largest of the Canadian banks by deposits and market cap. BNS is also the most international of the Canadian banks with exposure in 55 countries outside Canada. BNS saw a pause in its dividend growth during the financial crisis. However, BNS has started raising dividends after the crisis with a 5-yr DGR of 5.15%. I have a DRIP plan in BNS and invest monthly to this holding. My WatchlistI am also considering various stocks that are not currently in my portfolio, but the current high valuations do not provide many options.
Best Long Term Stocks To Buy Right Now: AMAG Pharmaceuticals Inc.(AMAG)
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients. AMAG Pharmaceuticals was founded in 1981 and is based in Lexington, Massachusetts.
Advisors' Opinion:- [By Monica Gerson]
AMAG Pharmaceuticals (NASDAQ: AMAG) shares fell 16% to $18.38 in the pre-market trading after the company received a CRL from the FDA for the supplemental NDA for Feraheme for broader IDA indication.
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Best Long Term Stocks To Buy Right Now: Koninklijke Ahold NV (AHONY)
Koninklijke Ahold N.V. (Ahold), incorporated on April 29, 1920, is engaged in the operation of retail food stores in the United States and Europe through subsidiaries and joint ventures. Ahold�� retail operations are presented in four segments: Stop & Shop/Giant-Landover, Giant-Carlisle, Albert Heijn and Albert/Hypernova. During the fiscal year ended January 3, 2010 (fiscal 2009), it operated 2,909 stores. On February 8, 2010, Ahold�� Giant-Carlisle acquired 25 stores from Ukrop�� Super Markets.
Franchisees operated 783 of the Albert Heijn, Etos and Gall & Gall stores, 463 of which were either owned by the franchisees or leased independently from Ahold. Of the 2,446 stores, 20% were company-owned and 80% were leased. Ahold�� stores range in size from 20 to over 10,000 square meters. Albert Heijn is a food retailer in the Netherlands. Etos is a health and beauty retailer in the Netherlands. Gall & Gall is a wine and liquor specialist in the Netherlands. Stop & Shop is a supermarket brand, operating in six states in the northeast United States. Giant-Landover is a supermarket brand, operating in four states in the mid-Atlantic United States. Peapod is an online grocery delivery service working in partnership with Stop & Shop and Giant-Landover. It also serves the metropolitan areas of Chicago, Illinois; Milwaukee and Madison, Wisconsin, and the northern areas of Indiana.
Advisors' Opinion:- [By Rich Duprey]
As mentioned, Kroger is still swallowing Harris Teeter and has said it needs time to make more acquisitions. Royal Ahold (NASDAQOTH: AHONY ) is also said to be leery about doing large acquisitions these days, while Cerberus recently finished acquiring the Albertsons and Acme chains from SUPERVALU (NYSE: SVU ) �for $3.3 billion.
Best Long Term Stocks To Buy Right Now: Chelsea Therapeutics International Ltd.(CHTP)
Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic arthritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.
Advisors' Opinion:- [By Lauren Pollock]
Chelsea Therapeutics International Ltd.(CHTP) said an offering of 6.67 million shares priced at $3 each, a 9.9% discount to Tuesday’s close. The development-stage pharmaceutical company said it intends to use the proceeds to fund its droxidopa program, including regulatory and possible initial commercialization activity for its lead investigational drug candidate Northera, and for general corporate purposes. Shares dropped.
- [By MONEYMORNING]
Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) is a 10-year-old development-stage biopharmaceutical company headquartered in Charlotte, N.C. Shares got our attention mid-month when the stock soared 160% on heavy volume after a panel of federal experts recommended approval of its most advanced candidate, Northera. A blood pressure treatment designed to prevent dizziness and fainting in Parkinson's disease patients, the advisory group concluded the drug is effective enough to warrant regulatory approval. The outside panel's endorsement came with the condition the drug only be approved for short-term use in a defined group of patients.
- [By John Udovich]
The biotech roller-coaster continues for investors into 2014 with small cap Chelsea Therapeutics International Ltd (NASDAQ: CHTP) set to more than double when the market opens today, meaning its time to take a closer look at what in the world is going on with the stocks plus take a closer look at the performance of biotech peers like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Bryan Murphy]
What do Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), National Bank of Greece (NYSE:NBG), and Walter Energy, Inc. (NYSE:WLT) have in common. They all have charts worth a much closer look right now. That's not to say they're all dropping the same bullish hint. In fact, WLT, NBG, and CHTP are all dropping distinctly-different hints as to their likely near-term future. But, trading action is trading action no matter which direction it's in. Take a look.
Yes: Truth be told, shares of the National Bank of Greece have been working on a rally for a while. It's only been recently, however, that NBG has made it clear it's not going to give up. The stock crossed above the 100-day moving average line (gray) early in the month, and has continued to peel away. Yes, National Bank of Greece hit something of a soft patch last week, but the 20-day moving average line (blue) has since stepped up to the plate as a technical floor, rekindling the uptrend yesterday day and today. Perhaps most bullish of all is the fact that NBG has started to increase volume on the way up, after it cleared the 100-day moving average line,
Best Long Term Stocks To Buy Right Now: Inergy L.P. (NRGY)
Inergy, L.P. engages in the storage and transportation of natural gas and natural gas liquids (NGL) in the United States and Canada. The company is also involved in the fractionation and distribution of NGL; and processing of natural gas and distribution of propane, marketing, and price risk management services to users, retailers, and resellers. In addition, it engages in the production and sale of salt products. The company owns and operates four natural gas storage facilities that include Stagecoach, Thomas Corners, Steuben, and Seneca Lake; natural gas transportation assets in New York and Pennsylvania; NGL storage facility in New York; and solution-mining and salt production company in New York. Its customers primarily include natural gas local distribution companies, electric generation companies, natural gas producers, other natural gas pipelines, and natural gas marketing companies. Inergy, L.P. founded in 2001 and is headquartered in Kansas City, Missouri.
Advisors' Opinion:- [By Dan Caplinger]
Consolidation has been the name of the game for growth in the propane industry lately, with some deals having made big changes to the industry over the past year. Last spring, Inergy (NYSE: NRGY ) decided to sell off its retail propane business to Suburban Propane (NYSE: SPH ) , vastly increasing Suburban's size while giving Inergy a big stake in its former rival. Meanwhile, Ferrellgas has continued its string of more modest acquisitions, with the company's buyout of privately held Western Petroleum marking the fifth purchase Ferrellgas has made since last August.
Best Long Term Stocks To Buy Right Now: BE Aerospace Inc.(BEAV)
BE Aerospace, Inc. designs, manufactures, sells, and services commercial aircraft and business jet cabin interior products worldwide. The company?s Commercial Aircraft segment offers seat frames, cushions, armrests, and tray tables; various optional features, such as adjustable lumbar supports, footrests, reading lights, head/neck supports, and other comfort amenities; oxygen storage, distribution, and delivery systems for commercial and business jet aircrafts; aircraft coffee and beverage makers, and coffee warmers and water boilers; convection, steam, and warming ovens; commercial aircraft refrigeration equipment; modular lavatory systems; vacuum waste water and galley systems; and thermal and power management solutions. This segment also offers engineering, design, integration, installation, and certification services for commercial aircraft passenger cabin interiors; in-house capabilities to design, manage, integrate, test, and certify reconfigurations and modificatio ns for commercial aircraft and to manufacture related products, including engineering kits and interface components; and interior reconfiguration services. Its Consumables Management segment provides inventory management and replenishment, electronic data interchange, special packaging and bar-coding, parts kitting, quality assurance testing, and purchasing assistance services; and creative and differential supply chain solutions, such as 3PL and 4PL programs. This segment also distributes aerospace fasteners and consumables. The company?s Business Jet segment offers a line of furnishings for business jets, including seating and sofa products, such as electric fully berthing lie flat seats, direct and indirect lighting, air valves, oxygen delivery systems, sidewalls, bulkheads, credenzas, closets, galley structures, lavatories, and tables; and super first class cabin interior products for commercial wide-body aircraft. The company was founded in 1987 and is headquartered in Wellington, Florida.
Advisors' Opinion:- [By Victor Selva] able to maintain a competitive position in the market, shows ATS麓s ability for great evolution and profitable growth.
Alliant also benefits from a narrow economic moat. Having long-term contracts with its customers, that generate consistent revenue for years, is a great advantage. The long-term programs have high switching costs for the customer. For example, ATK produced the composite materials for the Hellfire missile for years.
In addition, leading the solid rocket propellant market should ensure increased annual revenue. The new Space Launch System (SLS), for which ATK is working with the NASA, is expected be as successful as the Space Shuttle program years ago.
Most important, Alliant is the biggest supplier of small-caliber ammunition for the U.S. military. Furthermore, ATK has managed to get new contracts in the U.S. military sector, such as the second full-rate production of the advanced anti-radiation guided missiles. This contract with the U.S. Navy was signed for a total of $102.4 million.
New Contracts and acquisitions should increase profitability
Alliant has developed a composite technology that brought in new customers such as Airbus Group NV (EADSY) and Boeing Co (BA). In addition, the company's composite material is required for the production of the F-35 jets. ATK produces around $1.8 million of the content in every F-35 jet that is constructed and generates $1.2 million worth of every A350.
New acquisitions create great expectations for shareholders, and this is the case of Alliant. The acquisition of Bushnell Group Holding Inc., that was completed in November of 2013, will amplify the customer base of Alliant麓s Sporting Group even further, and is projected to increase earnings for the company.
Good Outlook for the Company�� Future Performance
The future looks bright for Alliant Techsystems Inc. The company麓s financial position will improve due to a better operating margin, cash flow opt
No comments:
Post a Comment